Schwartz B D, Luehrman L K, Rodey G E
J Clin Invest. 1979 Oct;64(4):938-47. doi: 10.1172/JCI109560.
Serologic cross-reactivity among allelic gene products commonly occurs in the HLA complex, but the molecular basis of these serologic phenomena is incompletely characterized. Because of strong cross-reactivity among antigens comprising the B7 cross-reactive group (i.e., HLA-B7, Bw22, B27, B40, and Bw42) and because of the association of several antigens of this group with spondyloarthropathies, we initiated a study of the chemical basis of cross-reactivity among this group of antigens. Using classic serologic procedures, 125I-Protein A binding assay, and chemical immunoprecipitation techniques, we have defined a new antigenic determinant, tentatively designated "X", which is present on certain HLA-B molecules. By a series of sequential immunoprecipitation experiments, X was shown to be a "public" antigenic determinant distinct from the "private" determinants B7, Bw22, B27, and B40, but present on the same 44,000-dalton glycoprotein molecules. The implications of this finding regarding disease predisposition and HLA typing as a diagnostic aid are discussed.
等位基因产物之间的血清学交叉反应在HLA复合体中普遍存在,但这些血清学现象的分子基础尚未完全明确。由于构成B7交叉反应组的抗原之间存在强烈的交叉反应(即HLA - B7、Bw22、B27、B40和Bw42),且该组中的几种抗原与脊柱关节病相关,我们启动了对该组抗原交叉反应化学基础的研究。使用经典血清学方法、125I - 蛋白A结合试验和化学免疫沉淀技术,我们确定了一种新的抗原决定簇,暂定为“X”,它存在于某些HLA - B分子上。通过一系列连续的免疫沉淀实验,X被证明是一种“公共”抗原决定簇,与“私有”决定簇B7、Bw22、B27和B40不同,但存在于相同的44,000道尔顿糖蛋白分子上。本文讨论了这一发现对疾病易感性以及作为诊断辅助手段的HLA分型的意义。